Taking a Tinder Approach to the Agency-Client Relationship

Taking a Tinder Approach to the Agency-Client Relationship

Imagine if you could choose your agency partners based on attributes most appealing to you. With a swipe to the right or left, you could secure them a roster position or doom them to languish in procurement.

15 unexpected Twitter responses to the "Who Pneu?" campaign

15 unexpected Twitter responses to the "Who Pneu?" campaign

Celebrity success or fail? Here's what the American Lung Association, Pfizer and Tim Daly likely did not see coming when they joined forces to raise awareness about pneumococcal pneumonia.

Five things for pharma marketers to know: Friday, February 5, 2016

Five things for pharma marketers to know: Friday, February 5, 2016

Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Health economic and outcomes research datasets have rarely been integral to product development and communication plans.

Ascension Health ups Ragone to chief marcomms officer

Ascension Health ups Ragone to chief marcomms officer

The Ketchum veteran joined the nonprofit healthcare system in mid-2014.

House Oversight committee upbraids Turing, Valeant execs

House Oversight committee upbraids Turing, Valeant execs

A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin departs Havas network for Klick Health in senior-staffing push

Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.

Five things for pharma marketers to know: Thursday, February 4, 2016

Five things for pharma marketers to know: Thursday, February 4, 2016

Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet

4 Industry Execs Examine the State of Physician-Rep Access

4 Industry Execs Examine the State of Physician-Rep Access

Recent polls paint a mixed picture of physicians' willingness to see pharma sales reps. What gives? Are no-see docs up or down, and what's behind the dissonant findings?

McCann Torre Lazur names new president

McCann Torre Lazur names new president

After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.

Johnson & Johnson comms leader stepping down

Johnson & Johnson comms leader stepping down

FitzPatrick is departing the company as it evaluates its 150 agency partnerships.

Making the Case for the Value of Co-pay Cards

Making the Case for the Value of Co-pay Cards

Now that payers are locking in discounts at launch from drugmakers, where do co-pay cards fit in the marketing mix?

Medical Advertising Hall of Fame inductees of 2016

Medical Advertising Hall of Fame inductees of 2016

A pharma research forefather. An agency builder. A "guy you wanted in the room." These Medical Advertising Hall of Fame inductees are a professionally diverse and richly worthy trio.

Five things for pharma marketers to know: Wednesday, February 3, 2016

Five things for pharma marketers to know: Wednesday, February 3, 2016

Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets

Speeding up FDA Approvals Calls for Pause

Speeding up FDA Approvals Calls for Pause

The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.

Orphan drug sales expected to grow 12% by 2020

Orphan drug sales expected to grow 12% by 2020

Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.

Five things for pharma marketers to know: Tuesday, February 2, 2016

Five things for pharma marketers to know: Tuesday, February 2, 2016

Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions

Dudnyk promotes Tobias to president after Powers

Dudnyk promotes Tobias to president after Powers

Plus other industry hires and changes

Natrel's Oppici Wades into Unbranded Cancer Ads

Natrel's Oppici Wades into Unbranded Cancer Ads

Here are some compelling campaigns that invoke a visceral response—you laugh, cry, even cringe—followed by a more thoughtful and inspired reaction to learn more.

Five things for pharma marketers to know: Monday, February 1, 2016

Five things for pharma marketers to know: Monday, February 1, 2016

AbbVie cuts 2016 sales estimate for Viekira Pak; Abbott to acquire Alere for $5.8 billion; Express Scripts to stop covering Valeant's Glumetza

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

A Competitive Market is Good for US Patients

A Competitive Market is Good for US Patients

We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.

Is This the End of Agency Diversification?

Is This the End of Agency Diversification?

DTC and OTC/wellness can borrow from mainstream consumer shops. Professional marketing may pose a tougher sell.

Eli Lilly's diabetes drugs drive sales

Eli Lilly's diabetes drugs drive sales

The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.

Sridhar Iyengar to be keynote speaker at the MM&M Transforming Healthcare Conference

Sridhar Iyengar to be keynote speaker at the MM&M Transforming Healthcare Conference

The Silicon Valley gadget guru who helped define the beyond-the-pill era will talk about embedding nontraditional capabilities into biopharma business models.

BMS CEO defends use of DTC to promote cancer drug

BMS CEO defends use of DTC to promote cancer drug

The drugmaker's CEO said the campaign helps dispel pessimism created from a history of cancer drugs that lack "significant value."

Five things for pharma marketers to know: Friday, January 29, 2016

Five things for pharma marketers to know: Friday, January 29, 2016

FDA approves Merck's HCV doublet regimen; Gilead CEO steps down; Clinton takes aim at Valeant price hikes

Marketers Rely on Email and Social Media, Rather than Face Time

Marketers Rely on Email and Social Media, Rather than Face Time

Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.

Novartis says slow Entresto sales due to limited access

Novartis says slow Entresto sales due to limited access

In many cases, the drug required physicians to request prior authorization.

Five things for pharma marketers to know: Thursday, January 28, 2016

Five things for pharma marketers to know: Thursday, January 28, 2016

Sales of cystic-fibrosis drug Orkambi higher than expected; new sensor tracks sweat; J&J develops clinical trial to find new way to treat depression

Hey Pharma—Chin Up, Fella!

Hey Pharma—Chin Up, Fella!

The traditional line of attack is genuine and requires little in the way of spin—yet still, every time a Turing rears its head, it gets blown back in small and indigestible pieces.

Tecfidera's DTC campaign boosts Web traffic and call volume

Tecfidera's DTC campaign boosts Web traffic and call volume

Biogen execs said a recently launched DTC campaign for Tecfidera is showing positive early signs.

InVentiv Health PR promotes O'Kane to MD

InVentiv Health PR promotes O'Kane to MD

Former Biosector 2 US MD Jeanine O'Kane was named inVentiv Health PR Group's US MD.

4 Ways to Create a Sustainable Pricing Model

4 Ways to Create a Sustainable Pricing Model

The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.

Five things for pharma marketers to know: Wednesday, January 27, 2016

Five things for pharma marketers to know: Wednesday, January 27, 2016

The FDA plans to release new guidance on advertising in 2016; Trump supports Medicare price negotiations; Novartis CEO: golden days of drug pricing are over

Medicines360 CEO battles for IUD access

Medicines360 CEO battles for IUD access

Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.

J&J CEO: Patients have higher expectations

J&J CEO: Patients have higher expectations

Faced with slowing sales, the company is in the early stages of developing value-added services that support better patient outcomes.

Johnson & Johnson Baby appoints AKQA as China AOR

Johnson & Johnson Baby appoints AKQA as China AOR

Following November pitch, WPP agency will handle digital strategy, creative and social in region.

Top 25 metabolic products, 2014-2015

Sanofi is the category leader. Its product, Lantus Solostar, brought in $5.27 billion in US sales between October 2014 and September 2015.

Diabetes R&D narrows in on glycemic control

Diabetes R&D narrows in on glycemic control

New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.

Marketing challenges remain in crowded metabolic market

Marketing challenges remain in crowded metabolic market

Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.

Five things for pharma marketers to know: Tuesday, January 26, 2016

Five things for pharma marketers to know: Tuesday, January 26, 2016

The FDA accepts bid for new label for Jardiance; Markey puts on a hold on Califf's FDA nomination; GSK is studying the Zika virus

Five things for pharma marketers to know: Monday, January 25, 2016

Five things for pharma marketers to know: Monday, January 25, 2016

Valeant CEO is recovering; three drugmakers partner for early-stage cancer research

Kantar Health names CEO of Europe

Kantar Health names CEO of Europe

Michel Murino, former CEO of southern Europe and France, will now head the company's regional operations in Europe.

Your PharmaScope 2016

Your PharmaScope 2016

If we don't clean up our act and do something about predatory pricing scandals, we'll wind up with Washington bureaucrats telling us what we can charge for our products.

Five things for pharma marketers to know: Friday, January 22, 2016

Five things for pharma marketers to know: Friday, January 22, 2016

NICE recommends Opdivo for skin cancer; Sanofi layoffs could be looming; Senators ask for feedback on Sovaldi investigation

FDA slams Pfizer subsidiary for "misleading" Precedex video

FDA slams Pfizer subsidiary for "misleading" Precedex video

The Office of Prescription Drug Promotion said Pfizer subsidiary Hospira omitted information and misbranded the drug

At Work With: Fingerpaint's Joe Acee

At Work With: Fingerpaint's Joe Acee

"A global launch of a type-2 diabetes drug. It was a four-year trail of cheers and tears."

Weber Shandwick reorganizes its healthcare practice

Weber Shandwick reorganizes its healthcare practice

The agency named a new chief strategist and creative director along with new leads for its Minnesota, Chicago and New York healthcare practices.

Five things for pharma marketers to know: Thursday, January 21, 2016

Five things for pharma marketers to know: Thursday, January 21, 2016

GSK CEO says consumer health business could be its own entity; regulatory setbacks cloud future of DMD treatments; OPDP slams YouTube video

A Company's Culture Begins on Day One

A Company's Culture Begins on Day One

If we were going to be one of a kind, we needed a staff that understood and had lived through what our clients were facing.

Five things for pharma marketers to know: Wednesday, January 20, 2016

Five things for pharma marketers to know: Wednesday, January 20, 2016

Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales

2016 Wellness Forecast: Smart Stuff, Angry Debates and More

2016 Wellness Forecast: Smart Stuff, Angry Debates and More

We love smart stuff. Smartwatches track our daily activity, smart fabrics monitor vital signs, smart shoes navigate our journeys and smart drugs boost cognitive functioning.

Medical publishers eye new ad viewability rules

Medical publishers eye new ad viewability rules

They will attempt to develop a new industry standard for digital advertising viewability, a much debated topic that has vexed the broader advertising industry.

Pharma marketing agencies merge to form Aventria Health Group

Pinnacle Health Communications and Franklyn Healthcom merge to offer "more complete" customer-centric solutions.

Five things for pharma marketers to know: Tuesday, January 19, 2016

Five things for pharma marketers to know: Tuesday, January 19, 2016

Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business

What the AMA's Proposed DTC Ban Overlooks

What the AMA's Proposed DTC Ban Overlooks

While DTC advertising does significantly impact consumer demand, most evidence suggests the majority of this demand benefits the overall state of consumer health.

Pharma companies turn to LinkedIn to engage

Pharma companies turn to LinkedIn to engage

Part of LinkedIn's appeal lies in the high level of engagement of its members and the potential for precise targeting of content and talent searches.

Five things for pharma marketers to know: Friday, January 15, 2016

Five things for pharma marketers to know: Friday, January 15, 2016

The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA's post-market drug tracking; WebMD denies acquisition talks

Healthline Media receives $95 million in equity funding

Healthline Media receives $95 million in equity funding

Summit Partners' investment in the health information site expected to aid the company's efforts to compete with sites like WebMD

How pharma can stay competitive in the digital world

How pharma can stay competitive in the digital world

Drugmakers seeking to develop "beyond-the-pill" digital initiatives have to be willing to engage patients in new ways, McKinsey & Company report finds.

Langland's Andrew Spurgeon on Simplicity in Ads

Langland's Andrew Spurgeon on Simplicity in Ads

Spurgeon on finding simplicity in Procter & Gamble's "The Boy Raised by Goats" and a moving campaign about disabilities.

Five things for pharma marketers to know: Thursday, January 14, 2016

Five things for pharma marketers to know: Thursday, January 14, 2016

Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients

Is Pharma Taking the Wrong Approach to Patient-Centricity?

Is Pharma Taking the Wrong Approach to Patient-Centricity?

Life-sciences companies often behave as though focusing on patient needs is simply a matter of asking, "How can we provide patients with more services?

American Girl: Pharma's New Empathy Model

American Girl: Pharma's New Empathy Model

The kits aren't likely to enhance American Girl's bottom line in any significant way, yet the flood of press coverage painted the company as compassionate in a way that few such organizations are.

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

Characters in DTC Ads Used with Little Reason

Characters in DTC Ads Used with Little Reason

Many of the characters we are now meeting do not appear to be directed at a patient insight or purposefully used to de-stigmatize a disease.

Former Greyhealth and CDM executives launch Minds + Assembly

Former Greyhealth and CDM executives launch Minds + Assembly

The healthcare agency debuts with Swedish-based pharma company Orexo as its first client.

Senate committee clears Califf as FDA head

Senate committee clears Califf as FDA head

Two senators, including presidential candidate Bernie Sanders, threatened to hold up his nomination.

New multiple myeloma drugs prompt cost-effectiveness report

New multiple myeloma drugs prompt cost-effectiveness report

The FDA in November approved three new drugs that treat the rare blood cancer.

Five things for pharma marketers to know: Tuesday, January 12, 2016

Five things for pharma marketers to know: Tuesday, January 12, 2016

HCPs sound off on CMS opioid proposal; Senate committee to decide if Califf gets FDA commissioner nod; Celgene names new CEO

2016 May Bring More Warning Letters, Guidance from FDA

2016 May Bring More Warning Letters, Guidance from FDA

It is worth noting that the FDA sent only nine warning letters last year, all focused on well-recognized violations, such as minimization of risk information and unsubstantiated claims.

McCann HumanCare names Mazzola as EVP, group creative director

McCann HumanCare names Mazzola as EVP, group creative director

Mazzola says healthcare advertising is having a watershed moment.

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

7 takeaways from StartUp Health's annual report

7 takeaways from StartUp Health's annual report

The digital health sector brought in an estimated $6 billion in funding in 2015.

Sanofi promotes Loew to lead global commercial operations

Sanofi promotes Loew to lead global commercial operations

Damian Braga, who held the role previously, retired after 27 years working for the drugmaker

Five things for pharma marketers to know: Friday, January 8, 2016

Five things for pharma marketers to know: Friday, January 8, 2016

GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars

Five things for pharma marketers to know: Thursday, January 7, 2016

Five things for pharma marketers to know: Thursday, January 7, 2016

Fitbit faces allegations of inaccurate heart monitoring; Viiv Healthcare to collaborate with Janssen; Guardant Health raises funding for its cancer blood tests

Weber Shandwick buys healthcare specialist ReviveHealth

Weber Shandwick buys healthcare specialist ReviveHealth

Nashville-based ReviveHealth posted $8.7 million in revenue in 2014.

Millennials advocate for technology and promotion at agencies but are slow to take risks

Millennials advocate for technology and promotion at agencies but are slow to take risks

Millennials at pharma agencies are driven and tech-savvy but also pay too much attention to promotion and the shape of their careers, say agency leaders.

Roche invests in oncology start-up

Roche invests in oncology start-up

The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.

Five things for pharma marketers to know: Wednesday, January 6, 2016

Five things for pharma marketers to know: Wednesday, January 6, 2016

Lilly's Jardiance starting to gain market share; Merck "raring" to make acquisitions; Sanofi said it will stop marketing Afrezza

Sanofi to stop marketing Afrezza, citing low Rx

Sanofi to stop marketing Afrezza, citing low Rx

Sanofi spent $3.75 million on advertising for Afrezza in the third quarter of 2015 yet the therapy only brought in about $2 million in revenue.

4A's announces plans to defend DTC

4A's announces plans to defend DTC

The American Association of Advertising Agencies said stopping calls for a ban on DTC is a top agenda item for the trade group in 2016.

Five things for pharma marketers to know: Tuesday, January 5, 2016

Five things for pharma marketers to know: Tuesday, January 5, 2016

Gilead's hep-C combo gets Breakthrough designation; Baxalta licences experimental cancer drugs; Novartis agrees to settle class-action lawsuit

Infographic: more on MM&M's Transformers

Infographic: more on MM&M's Transformers

As students, about 27% of MM&M's healthcare transformers received degrees in subjects that did not include health, business or technology.

Q&A: Why McCann Health set up a pharmacy focused agency

Q&A: Why McCann Health set up a pharmacy focused agency

A Q&A with Sandra Carey, president of the McCann Pharmacy Initiative, on the move to push pharmacy to the forefront.

Five things for pharma marketers to know: Monday, January 4, 2016

Five things for pharma marketers to know: Monday, January 4, 2016

The FDA approved 45 new drugs in 2015; Baxalta signs immuno-oncology deal; pharma M&A activity may slow this year

ICC and Pace merge, renamed Cure

ICC and Pace merge, renamed Cure

FCB Health opted to merge the two agencies and rebrand their US shops, which together plan to fill 40 open positions in 2016.

Ryan Olohan

Ryan Olohan

Ryan Olohan, National industry director, healthcare, Google

Halle Tecco

Halle Tecco

Halle Tecco, Managing director, Rock Health

Dr. Robert Wachter

Dr. Robert Wachter

Dr. Robert Wachter, Professor, chief of the division of hospital medicine, University of California, San Francisco

Ruchin Kansal

Ruchin Kansal

Ruchin Kansal, Executive director and head, business innovation, Boehringer Ingelheim

Aschkan Abdul Malek

Aschkan Abdul Malek

Aschkan Abdul Malek, CEO/co-founder, AlemHealth

Walter De Brouwer

Walter De Brouwer

Walter De Brouwer, Founder and CEO, Scanadu

Stephanie Bova

Stephanie Bova

Stephanie Bova, Senior director, Takeda Digital Accelerator, Takeda

Meg Columbia-Walsh

Meg Columbia-Walsh

Meg Columbia-Walsh, Global lead, digital healthcare, Cognizant

Zen Chu

Zen Chu

Entrepreneur in residence, Martin Trust Center for MIT

Michael Vinegra

Michael Vinegra

Michael Vinegar, director, medical e-strategy, Novartis

Sandra Elliott

Sandra Elliott

Sandra Elliott, VP, consumer technology and service development, Meridian Health

Email Newsletters